[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362400-105":59,"doc-detail-362400-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evaluation-of-targeted-and-immune-combination-therapies-in-a-rat-model-of-hormone-receptor-positive-breast-cancer","Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer","","Estrogen receptor (ER)-positive breast cancer is widely prevalent and generally responsive to endocrine therapies, yet immune checkpoint inhibitors (ICIs) show limited efficacy in this subtype. Prior work established that nitroso-N-methylurea-induced rat mammary tumors model immune-evasive mechanisms and heterogeneous ICI response. This study evaluates KMT5B/C and IKBKE targeting in combination with fulvestrant, TGFβ blockade, and αPD-L1, comparing monotherapies and combinations using flow cytometry and single-cell RNA sequencing. Fulvestrant plus αPD-L1 most effectively reduced tumor burden and regression, while A-196 reshaped tumor cell states to enhance antigen presentation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-targeted-and-immune-combination-therapies-in-a-rat-model-of-hormone-receptor-positive-breast-cancer/362400/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-targeted-and-immune-combination-therapies-in-a-rat-model-of-hormone-receptor-positive-breast-cancer/362400.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are immune checkpoint inhibitors less effective in ER-positive breast cancer?","Question",{"text":113,"@type":114},"ER-positive tumors typically show limited tumor-infiltrating lymphocytes and higher immune-suppressive cell abundance, which reduces responsiveness to ICIs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What rat model was used to evaluate combination therapies?",{"text":118,"@type":114},"Nitroso-N-methylurea (NMU)-induced mammary tumors in Sprague-Dawley outbred rats, which mimic immune escape mechanisms and ICI response heterogeneity observed in patients.",{"name":120,"@type":111,"acceptedAnswer":121},"Which treatment combination showed the strongest antitumor effect?",{"text":122,"@type":114},"Fulvestrant combined with αPD-L1, which produced regression of most existing tumors and reduced tumor burden during treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362400,1790305714,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \nEvaluation of targeted and immune combination therapies in arat model of hormone receptor–positive breast cancer  \nErnesto Rojas-Jimeneza, b,c, Triet M. Buia, b,c, Pengze Yana, b,c , Zheqi Lia, b,c, Marco Seehawera, b,c, Jun Nishidaa, b,c , Pierre Foidarta, b,c, Gordon J. Freemana,c , and Kornelia Polyaka, b,c, 1   \nContributed by Kornelia Polyak; received January 14, 2025; accepted December 30, 2025; reviewed by Jos Jonkers and Saraswati V. Sukumar  \nEstrogen receptor (ER) positive breast cancer is the most prevalent subtype, commonly responsive to endocrine therapies. Immune checkpoint inhibitors (ICIs) have limited efficacy in ER-positive disease, highlighting the need for the development of combination immunotherapies for these patients. We previously established that nitroso-N-methylurea-induced mammary tumors in outbred Sprague-Dawley rats mimic immune evasive mechanisms and the heterogeneity of ICI response observed in patients. We identified a “luminal growing” gene signature in ER-positive tumors, which correlated with tumor growth and immune-related differences. Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Fulvestrant emerged as the most effective treatment, inducing regression of most existing tumors and reducing on-treatment tumor burden when combined with αPD-L1. A-196, while ineffective as a monotherapy, demonstrated enhanced response when combined with αPD-L1 . Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced aluminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development ofKMT5B/C inhibitors to enhance the efficacy and broaden the applicability ofICI therapy in cancer patients.  \nbreast cancer | hormone receptor positive | immune checkpoint inhibitor | targeted therapy | endocrine therapy  \nBreast cancer is the most prevalent malignancy in women worldwide. Tumors are classified into subtypes based on the expression of estrogen (ER) and progesterone (PR) receptors and HER2, which guide treatment decisions. ER-positive tumors constitute the majority (~70%) of cases, particularly in postmenopausal women, and are treated with endocrine therapies alone or in combination with CDK4/6 inhibitors and other targeted therapies in more advanced cases ( 1, 2) . Despite advancements in therapeutic strategies, challenges remain, as a subset of patients experience recurrence or do not respond to treatment. For patients unresponsive to standard of care, immunotherapy has shown promise. However, ER-positive breast cancers typically exhibited limited tumor-infiltrating lymphocytes and an abundance of immune-suppressive cells, reducing their likelihood of responding to immune checkpoint inhibitors (ICI) (3). The limited success of ICI in ER-positive disease underscores the importance of understanding and modulating cancer cell phenotypes and the tumor microenvironment (TME) to enhance therapeutic outcomes.  \nThe development and testing of immunotherapies in ER-positive breast cancer have been hindered by the lack of immunocompetent animal models that accurately recapitulate the human disease. Carcinogen-induced rat mammary tumor models, developed and characterized over 50 y ago, are ER-positive and estrogen-dependent (4), but have been overlooked until recently due to challenges associated with their use, including the high number of mutations thought to be induced by the carcinogens and variability am","cbCaiuG2sBfOZpDq","https://ap.wps.com/l/cbCaiuG2sBfOZpDq","pdf",7386807,12,"English","# Significance\n# Background\n# Experimental strategy\n# Results\n## Fulvestrant and αPD-L1 synergy\n## Effects of KMT5B/C and IKBKE targeting","[{\"question\":\"Why are immune checkpoint inhibitors less effective in ER-positive breast cancer?\",\"answer\":\"ER-positive tumors typically show limited tumor-infiltrating lymphocytes and higher immune-suppressive cell abundance, which reduces responsiveness to ICIs.\"},{\"question\":\"What rat model was used to evaluate combination therapies?\",\"answer\":\"Nitroso-N-methylurea (NMU)-induced mammary tumors in Sprague-Dawley outbred rats, which mimic immune escape mechanisms and ICI response heterogeneity observed in patients.\"},{\"question\":\"Which treatment combination showed the strongest antitumor effect?\",\"answer\":\"Fulvestrant combined with αPD-L1, which produced regression of most existing tumors and reduced tumor burden during treatment.\"}]","Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer | PDF",1790147544,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e58731acbfa5f7d9b94fa5c1331cd0e7.webp",983,1316,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28393fb0de58a796130c3981c6733f86.webp",982,1315,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5abe80dd94b87776e1c5138a56ff10b9.webp",981,1313,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/318bbee4cca3a65e27d3d7d853ae25f0.webp",980,1312]